GlassScriptPhysician profile
Sarah E New
NPI 1598355174
$6,937.42
in general payments reported to CMS, 2019-2025
33 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $1,668 · 2023: $1,259 · 2024: $1,540 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984 · Travel and Lodging: $1,869 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.83 |
| Travel and Lodging | $1,869.43 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,706.20 | 2024-2025 | Inspire |
| Abbvie INC. | $570.16 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $516.07 | 2021-2023 | |
| Novo Nordisk INC | $448.60 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $386.62 | 2022-2023 | Mounjaro |
| Genzyme Corporation | $272.09 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $247.42 | 2021-2025 | |
| Optinose US, INC. | $153.62 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $150.92 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $141.98 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $133.73 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $116.24 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $109.35 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.39 | 2021-2023 | Xifaxan, Trulance |
| Dexcom, INC. | $101.23 | 2024 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.15 | 2021-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $90.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $75.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $69.81 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $60.35 | 2021-2023 | Farxiga, Breztri |
| Boston Scientific Corporation | $51.58 | 2021 | |
| Axsome Therapeutics, INC. | $47.09 | 2023-2025 | Sunosi |
| Inari Medical, INC. | $42.53 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $40.12 | 2022-2023 | Seglentis |
| Pfizer INC. | $32.46 | 2023 | |
| Merck Sharp & Dohme LLC | $30.49 | 2022-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Eisai INC. | $28.68 | 2021 | |
| Currax Pharmaceuticals LLC | $25.19 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $23.70 | 2022 | |
| Amarin Pharma, INC. | $22.68 | 2021 | |
| Organon LLC | $16.84 | 2023 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $15.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah New listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.